Obsessive-Compulsive Disorder Clinical Trial
— ØCDOfficial title:
The Efficacy of an OCD Prevention Programme for at Risk Adults: a Randomized Clinical Trial
The main purpose of this randomised clinical trial is to test the efficacy of a prevention program for adult who are at risk of developing OCD, thus constituting a form of tertiary prevention.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | April 1, 2024 |
Est. primary completion date | March 29, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - age over 18 Exclusion Criteria: - clinically diagnosed OCD - current psychiatric/psychotherapeutic treatment - personality disorder diagnosis - suicidal ideation |
Country | Name | City | State |
---|---|---|---|
Romania | Babes-Bolyai University, Faculty of Psychology and Educational Sciences, Department of Clinical Psychology and Psychotherapy | Cluj-Napoca |
Lead Sponsor | Collaborator |
---|---|
Babes-Bolyai University | Romanian National Authority for Scientific Research |
Romania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change from baseline in life quality on the WHOQOL-BREF after the intervention | The WHOQOL-BREF is a validated self-report instrument assessing life quality in adults.
Change = end of intervention score - baseline score |
Baseline and Week 2 | |
Other | Change from baseline in irrationality on the ATQ after the intervention | The ABS-AV is a validated self-report instrument assessing irrationality in adults. Possible scores range from 24 to 120 Change = end of intervention score - baseline score | Baseline and Week 2 | |
Other | Change from baseline in global health on the GHQ-12 after the intervention | The GHQ-12 is a validated self-report instrument assessing global health in adults.
Possible scores range from 0 to 36. Change = end of intervention score - baseline score |
Baseline and Week 2 | |
Primary | Change from baseline in OCD symptoms on the OCI-R after the intervention | The OCI-R is a validated self-report instrument assessing OCD symptoms. Possible scores range from 0 to 72. Change = end of intervention score - baseline score | Baseline and Week 2 | |
Primary | Change from baseline in depressive symptoms on the PHQ-9 after the intervention | The PHQ-9 is a validated self-report instrument assessing depressive symptoms. Possible scores range from 0 to 27.
Change = end of intervention score - baseline score |
Baseline and Week 2 | |
Primary | Change from baseline in anxiety symptoms on the GAD-7 after the intervention | The GAD-7 is a validated self-report instrument assessing anxiety symptoms. Possible scores range from 0 to 21.
Change = end of intervention score - baseline score |
Baseline and Week 2 | |
Secondary | Change from baseline in experiential avoidance on the EAQ after the intervention | The EAQ is a validated self-report instrument assessing experiential avoidance. Possible scores range from 15 to 90.
Change = end of intervention score - baseline score |
Baseline and Week 2 | |
Secondary | Change from baseline in cognitive distortions on the OBQ-44 after the intervention | The OBQ-44 is a validated self-report instrument assessing cognitive distortions in OCD. Possible scores range from 7 to 308.
Change = end of intervention score - baseline score |
Baseline and Week 2 | |
Secondary | Change from baseline in uncertainty intolerance on the IUS after the intervention | The IUS is a validated self-report instrument assessing intolerance of uncertainty. Possible scores range from 27 to 135.
Change = end of intervention score - baseline score |
Baseline and Week 2 | |
Secondary | Change from baseline in resilience on the RSA after the intervention | The RSA is a validated self-report instrument assessing resilience in adults. Possible scores range from 43 to 215.
Change = end of intervention score - baseline score |
Baseline and Week 2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04934007 -
Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder
|
N/A | |
Recruiting |
NCT04071990 -
Family Involvement in CBGT of OCD: a Randomized Controlled Trial
|
N/A | |
Completed |
NCT02541968 -
Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder
|
N/A | |
Recruiting |
NCT05651295 -
A Precision Medicine Approach to Target Engagement for Emotion Regulation
|
N/A | |
Recruiting |
NCT05391503 -
Light Therapy for Obsessive-compulsive Disorder (OCD)
|
N/A | |
Recruiting |
NCT04539951 -
Pragmatic Trial of Obsessive-compulsive Disorder
|
Phase 2 | |
Completed |
NCT03416504 -
Methods for Managing Intrusive Thoughts
|
N/A | |
Not yet recruiting |
NCT06029738 -
Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD
|
N/A | |
Recruiting |
NCT02844049 -
European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS
|
N/A | |
Terminated |
NCT02909660 -
What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder
|
N/A | |
Completed |
NCT02911324 -
Cannabinoid Medication for Adults With OCD
|
Phase 1/Phase 2 | |
Terminated |
NCT02234011 -
A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder
|
Phase 2 | |
Completed |
NCT02217995 -
Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients
|
N/A | |
Withdrawn |
NCT01953042 -
Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders
|
N/A | |
Completed |
NCT02655926 -
Deep Brain Stimulation for Severe Obsessive Compulsive Disorder
|
N/A | |
Terminated |
NCT00758966 -
Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder
|
Phase 2 | |
Completed |
NCT00742664 -
Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project
|
Phase 1/Phase 2 | |
Completed |
NCT04919785 -
Deep Brain Stimulation in Severe Obsessive-compulsive Disorder
|
N/A | |
Completed |
NCT00523718 -
Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder
|
Phase 2 | |
Completed |
NCT00074815 -
Treatment of Obsessive Compulsive Disorder in Children
|
Phase 3 |